179 related articles for article (PubMed ID: 18694944)
21. Primary antituberculosis drug resistance and acquired rifampicin resistance in Gujarat, India.
Trivedi SS; Desai SG
Tubercle; 1988 Mar; 69(1):37-42. PubMed ID: 3140458
[TBL] [Abstract][Full Text] [Related]
22. [Mechanisms of the action of drugs in the short-course chemotherapy].
Mitchison DA
Bull Int Union Tuberc; 1985; 60(1-2):36-40. PubMed ID: 2416374
[No Abstract] [Full Text] [Related]
23. Therapeutic effects of traditional Chinese medicine Niubeixiaohe in mouse tuberculosis models.
Liang Y; Wang X; Song J; Wang L; Chen D; Yang Y; Bai X; Wang J; Shi Y; Chen S; Liu J; Yang C; Luo H; Liu G; Wu X
J Ethnopharmacol; 2017 Jan; 195():318-323. PubMed ID: 27884716
[TBL] [Abstract][Full Text] [Related]
24. Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages.
Chanwong S; Maneekarn N; Makonkawkeyoon L; Makonkawkeyoon S
Tuberculosis (Edinb); 2007 Mar; 87(2):130-3. PubMed ID: 16860611
[TBL] [Abstract][Full Text] [Related]
25. [Antimicrobial resistance in tuberculosis].
Gutiérrez-Aroca JB; Ruiz P; Casal M
Rev Esp Quimioter; 2013 Dec; 26(4):332-6. PubMed ID: 24399346
[TBL] [Abstract][Full Text] [Related]
26. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment.
Hoff DR; Ryan GJ; Driver ER; Ssemakulu CC; De Groote MA; Basaraba RJ; Lenaerts AJ
PLoS One; 2011 Mar; 6(3):e17550. PubMed ID: 21445321
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Berberine as an Adjunct to TB Treatment.
Ozturk M; Chia JE; Hazra R; Saqib M; Maine RA; Guler R; Suzuki H; Mishra BB; Brombacher F; Parihar SP
Front Immunol; 2021; 12():656419. PubMed ID: 34745081
[TBL] [Abstract][Full Text] [Related]
28. [Determination of Mycobacterium tuberculosis' sensitivity to pyrazinamide on a BACTEC-960 bacteriological analyzer].
Irtuganova OA; Smirnova NS; Slogotskaia LV
Probl Tuberk Bolezn Legk; 2003; (7):40-2. PubMed ID: 12939878
[No Abstract] [Full Text] [Related]
29. [Bactericidal therapy in patients with tuberculosis].
Krasnov VA; Ursov IG
Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
[No Abstract] [Full Text] [Related]
30. Resistance patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Nairobi.
Ndung'u PW; Kariuki S; Ng'ang'a Z; Revathi G
J Infect Dev Ctries; 2012 Jan; 6(1):33-9. PubMed ID: 22240426
[TBL] [Abstract][Full Text] [Related]
31. Increasing drug resistance of Mycobacterium tuberculosis isolates in Ontario, Canada, 1987-1998.
Remis RS; Jamieson F; Chedore P; Haddad A; Vernich L
Clin Infect Dis; 2000 Aug; 31(2):427-32. PubMed ID: 10987700
[TBL] [Abstract][Full Text] [Related]
32. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
33. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
[TBL] [Abstract][Full Text] [Related]
34. The decline of high drug resistance rate of pulmonary Mycobacterium tuberculosis isolates from a southern Taiwan medical centre, 1996-2000.
Lu PL; Lee YW; Peng CF; Tsai JJ; Chen YH; Hwang KP; Chen TP
Int J Antimicrob Agents; 2003 Mar; 21(3):239-43. PubMed ID: 12636985
[TBL] [Abstract][Full Text] [Related]
35. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
36. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
Li W; Obregón-Henao A; Wallach JB; North EJ; Lee RE; Gonzalez-Juarrero M; Schnappinger D; Jackson M
Antimicrob Agents Chemother; 2016 Sep; 60(9):5198-207. PubMed ID: 27297488
[TBL] [Abstract][Full Text] [Related]
38. Primary and acquired resistance of Mycobacterium tuberculosis in Western Mexico.
Amaya-Tapia G; Martín-Del Campo L; Aguirre-Avalos G; Portillo-Gómez L; Covarrubias-Pinedo A; Aguilar-Benavides S
Microb Drug Resist; 2000; 6(2):143-5. PubMed ID: 10990269
[TBL] [Abstract][Full Text] [Related]
39. Correlation between resistance to pyrazinamide and resistance to other antituberculosis drugs in Mycobacterium tuberculosis strains isolated at a referral hospital.
Fonseca Lde S; Marsico AG; Vieira GB; Duarte Rda S; Saad MH; Mello Fde C
J Bras Pneumol; 2012; 38(5):630-3. PubMed ID: 23147056
[TBL] [Abstract][Full Text] [Related]
40. Gallium nitrate is efficacious in murine models of tuberculosis and inhibits key bacterial Fe-dependent enzymes.
Olakanmi O; Kesavalu B; Pasula R; Abdalla MY; Schlesinger LS; Britigan BE
Antimicrob Agents Chemother; 2013 Dec; 57(12):6074-80. PubMed ID: 24060870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
